Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HRZN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HRZN and 80,000+ other tickers.
See exactly how HRZN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HRZN and 80,000+ other tickers.
Horizon Technology Finance Corporation operates as a business development company (BDC) with a core focus on providing financing and making equity investments in businesses in their early growth phases. The firm primarily offers secured debt and venture loans to companies that have already secured funding from venture capital firms. Its investment interests span various industries, including technology, life sciences, healthcare information and services, and clean technology. Geographically, Horizon Technology Finance Corporation directs its investments towards companies situated within the United States.
FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $15 million senior credit facility to Bioness Medical, Inc. (“Bioness”), with an initial $10 million funded at closing, and up to $5 million available to support Bioness's continued growth. Bioness develops and commercializes FDA-approved neurorehabilitation technologies designed to improve mobility and function.
Shares of Horizon Technology Finance Corporation (NASDAQ: HRZN - Get Free Report) have been assigned a consensus rating of "Hold" from the seven analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating
Venture lending is the higher-octane corner of private credit. Business development companies, or BDCs, in this niche extend senior secured loans to venture-backed and lower-middle market private companies, then pass the interest income through to shareholders as dividends.
Horizon Technology Finance (HRZN) Q2 2026 Earnings Call Transcript
Horizon Technology Finance NASDAQ: HRZN said its second-quarter net asset value declined primarily because of write-downs tied to one portfolio company, even as the business development company expanded its debt investment portfolio for a third consecutive quarter and reported a larger committed backlog following its April merger with Monroe Capital Corporation.